The summaries are free for public
use. The Chronic Liver Disease
Foundation will continue to add and
archive summaries of articles deemed
relevant to CLDF by the Board of
Trustees and its Advisors.
Abstract Details
Albumin: Indications in chronic liver disease
Tufoni M1, Zaccherini G1, Caraceni P1, Bernardi M1. United European Gastroenterol J. 2020 Feb 26:2050640620910339. doi: 10.1177/2050640620910339. [Epub ahead of print]
Author information
1 Department of Medical and Surgical Sciences, S Orsola-Malpighi University Hospital, Bologna, Italy.
Abstract
Albumin is currently employed as a plasma expander to prevent and treat specific complications of cirrhosis with ascites, such as the prevention of paracentesis-induced circulatory dysfunction and renal dysfunction induced by spontaneous bacterial peritonitis, as well as the diagnosis and treatment of acute kidney injury and hepatorenal syndrome. Recently, evidence has shown that long-term albumin administration in patients with decompensated cirrhosis reduces mortality and incidence of complications, eases the management of ascites, is cost effective, and has a good safety profile.